The gastrointestinal tract is lined with a single layer of epithelial cells that separates the gut lumen from the connective tissue and the immune system ([@bib28]; [@bib33]). Because it is constantly exposed to dietary and environmental antigens and to an estimated community of 10^14^ commensal bacteria, the immune system is confronted with the difficult task of enforcing tolerance to innocuous environmental antigens while also protecting against invading pathogens. An aberrant immune response to the intestinal microbiota contributes to the pathogenesis of Crohn's disease (CD), a chronic inflammatory bowel disease (IBD) that affects genetically predisposed individuals ([@bib12]; [@bib35]).

Mononuclear phagocytes, which include a large population of macrophages (MΦ) and rare subsets of DCs, are critical for the establishment and maintenance of gut homeostasis ([@bib14]; [@bib57]). However, myeloid cell heterogeneity in phenotype, origin, and function has led to confusion over the classification between MΦ and DCs, especially in mucosal tissues ([@bib20]; [@bib37]). In murine tissues, CD11c is not an adequate marker to identify DCs because it is also expressed in varying levels on F4/80^+^ MΦ ([@bib36]; [@bib41]). This is in contrast to resident MΦ in human lamina propria (LP), which do not express CD11c ([@bib50]). In mice, macrophage--dendritic cell progenitors (MDPs) give rise to dedicated common DC precursors (precDCs) and monocytes via developmental pathways that are governed by Flt3L and M-CSF, respectively ([@bib32]). Both the CD103^+^CD11b^+^ and CD103^+^CD11b^−^ DC subsets originate from precDCs. Tissue-resident CD103^−^CX~3~CR1^+^ mononuclear phagocytes, which are the dominant population in the murine gut LP, derive from Ly6C^high^ circulating monocytes. Murine intestinal homeostasis has been demonstrated to critically depend on a delicate equilibrium between tolerogenic migratory CD103^+^CX~3~CR1^−^ DCs and pathogenic CD103^−^CX~3~CR1^+^ mononuclear phagocytes ([@bib25]; [@bib7]; [@bib56]). In fact, mice genetically depleted of CD103^+^ DCs and CX~3~CR1^+^ MΦ do not develop spontaneous inflammation ([@bib6]). Animals that have a predominance of CX~3~CR1^+^ cells in the LP develop exacerbated colitis ([@bib56]). However, both CX~3~CR1^+^F4/80^+^CD103^−^ LP MΦ and CD103^+^ DCs can induce gut tolerance through the generation and/or maintenance of the suppressive activity of Foxp3^+^ regulatory T cells, and CX~3~CR1 deficiency leads to exacerbated DSS-induced colitis ([@bib17]; [@bib52]; [@bib36]).

Recent studies have independently demonstrated that CD103^−^E-Cadherin^+^ and CD103^−^SIRP-α^+^ (CD172a) cells induce experimental colitis in mice ([@bib19]; [@bib49]). These pathogenic cells accumulate in the inflamed colons and/or LNs. The CD103^−^E-Cadherin^+^ cells originate from Ly6C^high^ circulating monocytes that migrate in a CCR7-independent manner to the mesenteric LNs (mLNs), whereas the CD103^−^CD172a^+^ DCs accumulate in the inflamed colons and mLNs via a CD47-dependent process. These cell populations promote T cell driven anti-CD40--mediated colitis and drive Th17-associated TNBS colitis in mice; the latter can be ameliorated by the administration of a CD47-Fc fusion protein that putatively targets the CD172a^+^ cells. Whether human equivalents of the colitogenic CD103^−^CD172a^+^ cells exist and whether they can be targeted by CD47-Fc in the mLNs (inductive site) and/or intestinal tissues (effector site) of CD patients remains unknown.

Previous studies have reported the presence of CD14^+^ MΦ in situ in the colons of CD patients ([@bib22]). Imaging analyses of intestinal mucosal tissues of CD patients have also revealed the existence of several distinct DC populations including DC-SIGN (CD209)^+^CD11c^+^ DCs, CD83^+^ DCs, CD103^+^ DCs, plasmacytoid DCs (pDCs) and Slan^+^ monocytes/DCs ([@bib16]; [@bib25]; [@bib54]; [@bib58]). In addition, a CD33^+^CD14^+^ intermediate MΦ/DC subset has been detected at similar frequencies throughout the nonlesional and lesional gut mucosa in CD patients ([@bib26]).

In this study, we provide compelling evidence for the accumulation of proinflammatory cytokine-producing HLA-DR^+^CD172a^+^ cells that coexpress or not E-Cadherin and CX~3~CR1 in the mLNs and inflamed mucosa of CD patients. These cells are a major source of IL-1β, IL-6, and TNF and can be targeted by an avidity-improved CD47 fusion protein (CD47-Var1) in inflamed CD tissues.

RESULTS
=======

HLA-DR^+^CD172a^+^ cells accumulate in the mLNs and inflamed intestinal mucosa of CD patients
---------------------------------------------------------------------------------------------

We first analyzed the mLNs and inflamed or noninflamed intestinal tissues of patients with CD or unrelated bowel disease (control/non-IBD) and searched for the human counterparts of the murine pathogenic CD103^−^CD172a^+^ DCs. HLA-DR^+^CD172a^+^ cells were detected in the mLNs ([Fig. 1 A](#fig1){ref-type="fig"}) and inflamed intestinal mucosa of CD patients ([Fig. 1 B](#fig1){ref-type="fig"}). The frequency of HLA-DR^+^CD172a^+^ cells was significantly increased in the mLN and LP mononuclear cell (LPMC) suspensions isolated from inflamed mucosal sites versus those samples isolated either from symptomless regions of CD patients or from control (non-IBD) specimens. The great majority of HLA-DR^+^CD172a^+^ cells from the mLNs were CD103^−^, whereas CD172a^+^CD103^+^ cells were detected in the inflamed gut tissues (unpublished data), corroborating previous observations in mice ([@bib25]). In human skin--derived LNs from healthy donors, CD172a appears to identify most HLA-DR^+^CD11c^+^ DCs, including CD14^+^ MΦ-like cells and resident DCs ([@bib46]). In this study, we found that CD11c expression in mLNs and gut tissues was limited to the HLA-DR^+^CD172a^+^ cell subset; HLA-DR^+^CD172a^−^ and HLA-DR^−^CD172a^−^ cells were CD11c^−^ ([Fig. 1 C](#fig1){ref-type="fig"}).

![**HLA-DR^+^CD172a^+^ cells are detected in increased proportions in the mLNs and intestinal tissues of CD patients.** Mesenteric LN cellular suspensions (mLNs) and LPMCs were prepared from control (non-IBD, diverticulosis) and CD patients (noninflamed and inflamed intestinal tissues). (A and B) Flow cytometry plots of HLA-DR and CD172a expression and the percentages of HLA-DR^+^CD172a^+^ cells. *n* = 9 controls and *n* = 11 CD patients (mLNs; A) and *n* = 5 controls and *n* = 9 CD patients (LPMC; B). Data are presented as the mean ± SEM. Unpaired, two-tailed Student's *t* test with Welch correction (mLNs and LPMC, controls versus CD patients) and paired, two-tailed Student's *t* test after Log~10~ transformation (LPMC, noninflamed versus inflamed) were used to assess significance. (C) Flow cytometry histograms of CD11c, CD14, DC-SIGN, E-Cadherin, and CX~3~CR1 expression in the HLA-DR^−^CD172a^−^ (thin lines), HLA-DR^+^CD172a^−^ (shaded lines), and HLA-DR^+^CD172a^+^ gated cells (bold lines). Representative of at least five CD patients. (D) Representative dot plots for E-Cadherin and CX~3~CR1 expression by HLA-DR^+^CD172a^+^ gated cells, and the percentage of the cell population in each quadrant. *n* = 5 controls and *n* = 9 CD patients (mLNs); *n* = 5 controls and *n* = 8 CD patients (LPMC). Data are presented as the mean ± SEM. Unpaired, two-tailed Student's *t* test with Welch correction (mLNs and LPMC, controls versus CD patients) and paired, two-tailed Student's *t* test after Log~10~ transformation (LPMC, noninflamed versus inflamed) were used to assess significance. (E) The percentages of HLA-DR^+^CD1c^+^ and HLA-DR^+^CD123^+^ cells. *n* = 4 controls and *n* = 8 CD patients (mLNs); *n* = 6 CD patients (LPMC). Data are presented as the mean ± SEM. \*, P \< 0.05; \*\*, P \< 0.01.](JEM_20122037_Fig1){#fig1}

We next determined which of the resident DC subsets, CD14^+^ MΦ-like cells or the recently described monocyte-derived DC-SIGN (CD209)^+^ DCs (Mo-DCs; [@bib13]), accumulated in the mLNs and intestinal mucosa of CD patients. CD14 and DC-SIGN were expressed by ∼50% of the HLA-DR^+^CD172a^+^ cells in the mLNs ([Fig. 1 C](#fig1){ref-type="fig"}). Notably, a significant fraction of HLA-DR^+^CD172a^+^CD11c^+^ cells coexpressed CD14 and DC-SIGN in the mLNs (unpublished data). In the LP, CD14 marked the majority of HLA-DR^+^CD172a^+^ cells but not the HLA-DR^+^CD172a^−^ cells ([Fig. 1 C](#fig1){ref-type="fig"}). In situ analysis by IHC further revealed that CD172a expression was scattered throughout the mucosa in the inflamed colons (unpublished data), a region populated by recently recruited CD14^+^ MΦ in CD patients ([@bib22]). In this regard, the HLA-DR^+^CD172a^+^CD11c^+^CD14^+^ cells observed in the gut mucosa appeared to be distinct from the human resident LP MΦ because the latter are characterized as CD11c^−^CD14^−^CD11b^−^CD13^+^HLA-DR^+^ cells ([@bib26]; [@bib51]). Of note, the HLA-DR^+^CD172a^+^ LP cell population also included regulatory MΦ (CD206^+^ cells) and, in agreement with recent studies, the CD206^+^/HLA-DR^+^ cell ratio was decreased in the inflamed versus noninflamed portions of the mucosa of CD patients (unpublished data; [@bib60]).

In mice, E-Cadherin marks a murine colitogenic DC subset that can be directly recruited from the blood to the mLNs ([@bib49]), whereas the CD103^−^CX~3~CR1^+^ mononuclear gut phagocytes originate from Ly6C^high^ monocytes that are recruited to the inflamed mucosal tissues and differentiate into CX~3~CR^low^ CD11b^+^ cells ([@bib5]; [@bib41]; [@bib4]). Further phenotypic analysis revealed that a significant proportion of the HLA-DR^+^CD172a^+^ cells expressed E-Cadherin or CX~3~CR1 in lymphoid and nonlymphoid CD tissues ([Fig. 1 C](#fig1){ref-type="fig"}). When the HLA-DR^+^CD172a^+^ cells were further subdivided according to E-Cadherin and CX~3~CR1 expression, it appeared that the CX~3~CR1^−^E-Cadherin^−^ cells predominated over the CX~3~CR1^+^E-Cadherin^+^ cells in both the mLNs and LP ([Fig. 1 D](#fig1){ref-type="fig"}). Importantly, these two cell populations, together with the CX~3~CR1^−^E-Cadherin^+^ cells, significantly accumulated in the mLNs and inflamed gut mucosa of CD patients. The frequency of CX~3~CR1^+^E-Cadherin^−^ cells was augmented in the LP but not in the mLNs of CD donors. In fact, the CX~3~CR1^+^ cells in the mLNs coexpressed CD1c but not CD123 and are thus considered to be conventional DCs. The percentage of HLA-DR^+^CD172a^+^ CD1c^−^CD123^−^ cells significantly increased in the samples from CD patients, further indicating that the HLA-DR^+^CD172a^+^ cells that accumulated in the mLNs are distinct from resident DCs (unpublished data). Notably, similar proportions of CD1c and CD123 DC subsets were detected in the mLNs and gut tissues of control and CD patients ([Fig. 1 E](#fig1){ref-type="fig"}).

Collectively, these findings provide the first evidence for the detection and accumulation of HLA-DR^+^CD172a^+^ cells in the lymphoid and mucosal tissues of CD patients, regardless of their expression of CX~3~CR1 and/or E-Cadherin.

TNF and IL-1β are selectively produced by CD172a^+^ cells in the peripheral tissues of CD patients
--------------------------------------------------------------------------------------------------

We next evaluated the proinflammatory profile of HLA-DR^+^CD172a^+^ cells in peripheral tissues. As depicted in [Fig. 2](#fig2){ref-type="fig"}, mLN cells and ex vivo--isolated LPMCs from CD patients spontaneously expressed IL-1β and TNF without the addition of exogenous stimuli. Notably, the CD172a^+^ but not CD172a^−^ cells represented the major source of spontaneous IL-1β and TNF production ([Fig. 2 A](#fig2){ref-type="fig"}). The frequency of CD172a^+^ IL-1β^+^ or TNF^+^ cells in the mLNs and inflamed intestinal mucosa from CD patients was significantly higher compared with in noninflamed or control specimens ([Fig. 2 B](#fig2){ref-type="fig"}). In fact, TNF and IL-1β were coproduced by ∼15--50% of the HLA-DR^+^CD172a^+^ cells, which mainly comprised the CX~3~CR1^−^E-Cadherin^−^ and CX~3~CR1^+^E-Cadherin^−^ subsets in mLNs and LPMC, respectively ([Fig. 2 C](#fig2){ref-type="fig"} and not depicted). Thus, these data indicate that proinflammatory cytokine production is restricted to CD172a^+^ cells in CD patients.

![**Proinflammatory cytokine production is restricted to CD172a^+^ cells in the mLNs and LPMC from CD patients.** Freshly isolated mLN cells and ex vivo isolated LPMC were stained for cell surface CD172a and HLA-DR followed by intracytoplasmic staining for IL-1β and TNF in the absence of brefeldin. (A) Representative flow cytometry plots of CD172a and IL-1β or TNF expression among total CD45^+^ cells. (B) Percentages of CD172a^+^IL-1β^+^ cells and CD172a^+^TNF^+^ cells. *n* = 4 controls and *n* = 10 CD patients (mLNs) and *n* = 6 controls and *n* = 15 CD patients (LPMC). Data are presented as the mean ± SEM. Unpaired, two-tailed Student's *t* test after Log~10~ transformation (mLN and LPMC, controls versus CD patients), and paired, two-tailed Student's *t* test after Log~10~ transformation (LPMC, noninflamed versus inflamed) were used to assess significance. \*, P \< 0.05; \*\*, P \< 0.01. (C) Representative flow cytometry plots of coexpression of IL-1β and TNF on HLA-DR^+^CD172a^+^ gated cells.](JEM_20122037_Fig2){#fig2}

A CD47 fusion protein specifically identifies HLA-DR^+^CD172a^+^ cells in the blood, mLNs, and mucosa of CD patients
--------------------------------------------------------------------------------------------------------------------

We therefore examined the possibility of selectively targeting these proinflammatory cytokine-producing cells in peripheral tissues of CD patients through CD172a. However, the most commonly used anti-CD172a mAb, clone SE5A5, which was used in the present study, was initially reported to also recognize an epitope common to both human CD172a and CD172b ([@bib48]), and none of the commercially available mAbs specifically recognize CD172a ([@bib62]). Because CD47 is a specific receptor for CD172a (SIRPα) but not for CD172b ([@bib9]; [@bib31]), and CD47-Fc prevents the development and relapse of colitis when administered to mice ([@bib19]), we first compared the binding characteristics of a newly developed avidity-improved human CD47 fusion protein (CD47-Var1) to CD172a mAb in the blood of control donors ([Fig. 3](#fig3){ref-type="fig"}). Human blood monocytes can be subdivided into two major subsets: CD14^bright^CD16^+or−^ and CD14^dim^CD16^+^Slan^+or−^ cells ([@bib42]; [@bib15]). Accordingly, we examined CD172a in relation to Slan expression within the circulating HLA-DR^+^ cells. CD172a mAb stained CD14^bright^ cells, which are reported to be the circulating precursors of intestinal CD14^+^ Mϕ in CD patients ([@bib23]). The CD14^dim^CD16^+^Slan^+^ cells that infiltrated CD ileum ([@bib16]) appeared as CD172a^dim^ ([Fig. 3 A](#fig3){ref-type="fig"}). In contrast, CD47-Var1 specifically marked CD14^bright^ cells but not Slan^+^ cells, despite both cell subsets expressing similar levels of CD172b. This indicates that CD47-Var1 does not bind to CD172b and that Slan^+^ cells express low or no CD172a ([Fig. 3, B and C](#fig3){ref-type="fig"}). In fact, CD47-Var1 binding significantly correlated with the expression of CD172a but not CD172b on CD14^bright^ monocytes ([Fig. 3 D](#fig3){ref-type="fig"}). Notably, the IC~50~ of the bond between HLA-DR^+^ cells and CD47-Var1 (1.4 nM) was 70-fold higher than that previously reported for CD47-Fc (100 nM; [@bib8]) ([Fig. 3 E](#fig3){ref-type="fig"}).

![**CD47-Var1 selectively detects HLA-DR^+^CD172a^+^ cells in blood and peripheral tissues.** HLA-DR^+^CD172a^+^ cells were analyzed in PBMC (A, B, F, and G) or whole blood (hemolyzed; C--E). (A and B) Representative flow cytometry plots of CD172a mAb (A) or CD47-Var1 or IgG1 control fusion protein (B) staining together with MHC class II (HLA-DR), Slan, CD14, and CD16 mAbs. Data were representative of five experiments. (C) MFI of CD47-Var1 binding and CD172b staining on CD14^bright^ monocytes or CD14^dim^Slan^+^ cells. *n* = 22. The bars in the graphs represent the means. Unpaired, two-tailed Student's *t* test (IgG1 control versus CD47-Var1 or CD172b) was used to assess significance. (D) Correlation between the MFI of CD47-Var1 and CD172a or CD172b expression on CD14^bright^ monocytes. *n* = 20. Two-tailed Pearson's correlation test (between CD172a or CD172b and CD47-Var1) was used to assess significance. (E) Inhibition of CD47-Var1 binding on CD14^bright^ monocytes by unlabeled CD47 fusion protein (CD47-Fc), CD47-Var1, or IgG1 control. Data are representative of six experiments. (F) Percentages of HLA-DR^+^CD47-Var1^+^ cells in PBMCs from controls and CD patients. *n* = 12 controls and *n* = 14 CD patients. Data are presented as the mean ± SEM. Unpaired, two-tailed Student's *t* test (controls versus CD patients) was used to assess significance. (G) MFI ratio of CD47-Var1 or CD172b by CD14^bright^ monocytes from controls and CD patients. *n* = 13 controls and *n* = 12 CD patients. Data are presented as box-and-whiskers plots with 10--90%iles. Unpaired, two-tailed Student's *t* test with Welch correction (controls versus CD patients) was used to assess significance. (H) Representative flow cytometry plots of HLA-DR and CD47-Var1 expression, the percentages of HLA-DR^+^CD47-Var1^+^ cells, and correlation between the percentage of HLA-DR^+^CD172a^+^ and the percentage of HLA-DR^+^CD47-Var1^+^ cells in mLNs and LPMCs. *n* = 7 controls and *n* = 11 CD patients (mLNs) and *n* = 7 CD patients (LPMCs). Data are presented as the mean ± SEM. Unpaired, two-tailed Student's *t* test with Welch correction (mLNs, controls versus CD patients), paired, two-tailed Student's *t* test (LPMC, noninflamed versus inflamed), and two-tailed Pearson's correlation test (between CD172a and CD47-Var1) were used to assess significance. \*, P \< 0.05; \*\*, P \< 0.01; \*\*\*, P \< 0.001.](JEM_20122037_Fig3){#fig3}

CD47-Var1 identified ∼10--15% of HLA-DR^+^ cells in the blood of control and CD patients ([Fig. 3 F](#fig3){ref-type="fig"}). However, CD172a (CD47-Var1 binding) but not CD172b expression was significantly increased on the CD14^bright^Slan^−^ cells in CD patients when compared with non-IBD patients, indicating that CD172a is highly expressed on circulating CD14^bright^ HLA-DR^+^ cells in CD patients ([Fig. 3 G](#fig3){ref-type="fig"}). Finally, we demonstrated that HLA-DR^+^CD47-Var1^+^ cells could also be detected in the mLNs and intestinal mucosa ([Fig. 3 H](#fig3){ref-type="fig"}). The percentages of HLA-DR^+^CD47-Var1^+^ cells significantly increased in the mLNs of CD patients as well as in LPMC from the inflamed tissue when compared with mLNs of control patients or noninflamed tissues from CD patients and correlated with the percentage of HLA-DR^+^CD172a^+^ cells. The frequency of HLA-DR^+^ cells stained with CD172a mAb tended to be higher than that identified by CD47-Var1 in mLNs, suggesting the presence of HLA-DR^+^CD172b^+^ cells with low CD172a expression in lymphoid organs.

CD47-Var1 therefore selectively identifies CD172a but not CD172b on HLA-DR^+^ cells that accumulate in the mLNs and intestinal mucosa of CD patients, and thus can be used to target proinflammatory cytokine-producing cells in CD tissues.

CD172a^+^ cells can be targeted by CD47-Fc in the peripheral tissues of CD patients
-----------------------------------------------------------------------------------

We have previously reported that CD47-Fc alters the migration and function of in vitro--generated human Mo-DCs ([@bib31]; [@bib8]), and in this study we have provided evidence that HLA-DR^+^CD172a^+^ cells are detected by CD47-Var1 in lymphoid and nonlymphoid CD tissues. We first added CD47-Var1 to colonic tissue explant cultures and examined the proinflammatory cytokine profile by Multi-Analyte Profiling (MAP) technology. The inflamed CD tissues (mean of 5 CD patients) displayed a pronounced proinflammatory profile when compared with noninflamed tissues, as indicated by a panel of 47 cytokines ([Fig. 4 A](#fig4){ref-type="fig"}). We demonstrated that exposure of inflamed mucosal explants to CD47-Var1 but not IgG1 control strongly suppressed the release of a large panel of cytokines from the inflamed tissue without significantly affecting the secretion of cytokines by the noninflamed tissues in CD patients ([Fig. 4 B](#fig4){ref-type="fig"}). Noteworthy, CD47-Var1 significantly dampened the production of proinflammatory cytokines, including IL-1β, IL-6, IL-8, TNF, IFN-γ, and, to a lesser extent, IL-23, as well as the monocyte chemoattractants MIP-1α and MIP-1β. More precisely, the inhibition of proinflammatory cytokine production by CD47-Var1 protein was observed in surgical specimens prepared from six patients who failed to respond to anti-TNF therapy ([Fig. 4 C](#fig4){ref-type="fig"}). In contrast, CD47-Var1 did not suppress IL-18 and MCP-1 release, whereas it decreased the production of IL-10.

![**CD47-Var1 inhibits proinflammatory cytokine release by inflamed intestinal tissue from CD patients.** Colonic tissue explants were cultured in the presence of CD47-Var1 or IgG1 control. The cytokine production profile was examined in the culture supernatants. The production of 47 cytokines was normalized to the absolute amount (ng or μg) of cytokine secreted by 100 mg of colonic tissue. (A) Scatter plot of cytokine production in noninflamed (x axis) versus inflamed (y axis) tissues. Data are presented as the mean of 5 independent experiments (*n* = 5 CD patients). Two-tailed Wilcoxon matched pairs signed rank test (noninflamed versus inflamed) was used to assess significance. (B) Scatter plot of cytokine production in explant cultures expressed as the ratio of CD47-Var1/IgG1 control for inflamed (x axis) versus noninflamed (y axis) tissues. Values \<1 on the x axis reflect the inhibition by CD47-Var1 in inflamed tissue. Data are the mean from five independent experiments (*n* = 5 CD patients) (C) Cytokine release in noninflamed and inflamed tissues in CD47-Var1-- or IgG1 control-treated explant cultures. *n* = 8 CD patients. Paired, two-tailed Student's *t* test after Log~10~ transformation (noninflamed versus inflamed and IgG1 control versus CD47-Var1) was used to assess significance. \*, P \< 0.05; \*\*, P \< 0.01; \*\*\*, P \< 0.001.](JEM_20122037_Fig4){#fig4}

We next confirmed that among HLA-DR^+^ cells, CD47-Var1^+^ cells represented the main producers of IL-1β and TNF in the inflamed LPMC and extended these observations to IL-6, IL-8, and IL-10 ([Fig. 5 A](#fig5){ref-type="fig"}). Accordingly, the HLA-DR^+^CD47-Var1^−^ cells were found to be negative for intracellular cytokines in the intestinal mucosa from CD patients. However, neutrophils (CD45^dim^CD66b^+^HLA-DR^−^ cells) were observed in the inflamed LP tissues of a subgroup of CD patients and were found to be CD47-Var1^dim^ ([Fig. 5 B](#fig5){ref-type="fig"}). In this patient subgroup, neutrophils but not CD45^+^CD47-Var1^−^ cells expressed TNF, IL-6, IL-8, and IL-10 but low levels of IL-1β. These results indicate that neutrophils may represent an additional target for CD47-Var1 in inflamed colons and further demonstrate that cytokine expression is restricted to CD172a^+^ cells in hematopoietic cells, whether or not they express HLA-DR.

![**CD47-Var1 identifies cytokine-producing HLA-DR^+^ and HLA-DR^−^ CD172a^+^ cells in inflamed colons from CD patients.** Ex vivo--isolated LP cells from inflamed colons of CD patients were stained for intracellular cytokines (IL-1β, TNF, IL-6, IL-8, and IL-10). (A) Representative flow cytometry plots of CD47-Var1 and cytokine expression among HLA-DR^+^ cells. (B) CD45 and CD47-Var1 expression was analyzed on total hematopoietic (CD45^+^) and nonhematopoietic (CD45^−^) cells. CD45^+^ cells were further subdivided according to HLA-DR and CD66b expressions. Intracellular expression of cytokines (IL-1β, TNF, IL-6, IL-8, and IL-10) was examined on CD45^+^CD47-Var1^−^ (shaded lines), CD45^dim^CD47-Var1^dim^HLA-DR^−^CD66b^+^ (thin lines), and CD45^hi^CD47-Var1^hi^HLA-DR^+^CD66b^−^ (bold lines) gated cells. Data are representative of at least three independent experiments.](JEM_20122037_Fig5){#fig5}

Finally, we addressed whether CX~3~CR1^+^ or CX~3~CR1^−^HLA-DR^+^CD172a^+^ cell subsets purified from the mLNs of CD patients could activate effector memory CD4 T cells isolated from the same mLN donor, and examined how CD47-Var1 interfered with Th cell fate ([Fig. 6](#fig6){ref-type="fig"}). Effector memory CD45RA^−^CD25^−^CD62L^low^ CD4^+^ T cells were purified as high (CCR7^−^) and low (CCR7^+^) IL-17 plus IFN-γ--producing cells ([@bib30]) and co-cultured with CD14^+^CX~3~CR1^+^ (P1), CD14^−^CX3CR1^+^ (P2; CD1c^+^DCs), or CD14^−^CX3CR1^−^ (P3, which may include E-Cadherin^+^ cells) HLA-DR^+^CD172a^+^ cells ([Fig. 6, A to C](#fig6){ref-type="fig"}). CD47-Var1 significantly impaired Th17 but not Th1 responses selectively in P3/CD62L^low^CCR7^−^ T cell co-cultures ([Fig. 6 D](#fig6){ref-type="fig"}). More specifically, CD47-Var1 suppressed the emergence of IL-17^+^IFN-γ^−^ and IL-17^+^IFN-γ^+^, but not IL-17^-^IFN-γ^+^ cells in CD62L^low^CCR7^−^ and CD62L^low^CCR7^+^ effector memory CD4 T cells co-cultured with P3 cells ([Fig. 6, E and F](#fig6){ref-type="fig"}).

![**CD47-Var1 impairs memory Th17 and Th17/Th1, but not Th1, responses by CD62L^lo^CD4 effector T cells co-cultured with HLA-DR^+^CD172a^+^ cells isolated from mLNs of CD patients.** (A) Two subsets of effector memory CD62L^lo^CD4 T cells (CCR7^−^ and CCR7^+^) gated on CD8^−^CD4^+^CD45RA^−^CD25^−^T cells were purified from mLN cellular suspension of CD patients. (B) CCR7^−^ and CCR7^+^ T cells were cultured in the presence of IL-2 for 24 h, and intracytoplasmic staining for IL-17 and IFN-γ was performed after PMA/ionomycin restimulation. (C) Three subpopulations (CD14^+^CX~3~CR1^+^, P1; CD14^−^CX~3~CR1^+^, P2; and CD14^−^CX~3~CR1^−^, P3) of HLA-DR^+^CD172a^+^ cells were purified from mLNs of CD patients. (A--C) Representative flow cytometry plots (*n* = 5 CD donors). (D to F) CCR7^−^ and CCR7^+^ T cells were co-cultured with autologous P1 (*n* = 4), P2 (*n* = 3), or P3 (*n* = 5) subsets at a 5:1 ratio for 5 d in the presence of *Staphylococcus aureus cowan 1* and CD47-Var1 or IgG1 control. Intracytoplasmic expression of IL-17 and IFN-γ was analyzed on CD2^+^ cells after PMA/ionomycin restimulation (mean ± SEM; D). Representative dot plots of IL-17 and IFN-γ staining in T cell/P3 co-culture (E) Data are the mean ± SEM from five independent experiments (P3) (F). Paired, two-tailed Student's *t* test after Log~10~ transformation was used to assess significance. \*, P \< 0.05.](JEM_20122037_Fig6){#fig6}

In summary, we conclude that the human counterparts of the murine colitogenic CD172a^+^ DCs, identified as proinflammatory cytokine producing HLA-DR^+^CD172a^+^ cells, accumulate in the mLNs and intestinal mucosa of CD patients and can be targeted by CD47 fusion proteins.

DISCUSSION
==========

Several studies in animal models support a role for DCs in the pathogenesis of IBD ([@bib14]), yet the nature and functional properties of the human counterparts of these colitogenic CD172a^+^ DCs has not been reported. Here, we show that HLA-DR^+^CD172a^+^ cells accumulate in the mLNs and the inflamed intestinal mucosa of CD patients, and demonstrate that IL-1β, TNF, IL-6, IL-8, or IL-10 production is selectively produced by CD172a^+^ but not CD172a^−^ cells. In inflamed intestinal tissue explants, CD47-Var1, which specifically binds CD172a, profoundly inhibits the production of a wide array of proinflammatory cytokines, and in mLNs it impairs the ability of HLA-DR^+^CD172a^+^ cells to stimulate memory Th17 but not Th1 responses. We conclude that HLA-DR^+^CD172a^+^ cells may contribute to CD pathogenesis at effector and inductive sites and can be targeted therapeutically by a CD47 fusion protein.

The delineation between DCs, MΦ, and the more recently described inflammatory Mo-DCs, in terms of phenotype, molecular signature, and function remains an open and highly debated issue in both murine and human tissues, especially in mucosal sites ([@bib56]; [@bib20]; [@bib37]; [@bib41]; [@bib39]; [@bib47]). In agreement with a previous study ([@bib58]), we found that the classical resident DCs (CD14^−^CX~3~CR1^+^CD1c^+^) and pDCs (CD14^−^CX~3~CR1^−^CD123^+^) are found in similar proportions in noninflamed and inflamed mLNs and colons, and are thus unlikely to represent a recruited cell population. In human LPMC, we showed that \>90% of the HLA-DR^+^CD172a^+^ cells displayed CD14, whereas it was expressed by ∼50% of these cells in the mLNs. In this regard, the HLA-DR^+^CD172a^+^CD14^+^ colonic cells resemble the CD14^+^ MΦ subpopulation detected in situ in intestinal CD tissues ([@bib22]) and the so-called intermediate CD14^+^CD33^+^CD16^−^CD68^+^CX~3~CR1^+^CD70^−^CD123^+^CD1c^−^ MΦ/DCs. However, the latter are detected throughout the gut mucosa of IBD patients ([@bib26]). The intestinal intermediate CD14^+^ MΦ/DC subset drives naive T cell differentiation into Th1 and Th17 cells in vitro ([@bib27]), and thus they might fulfill the DC criteria. Furthermore, half of the HLA-DR^+^CD172a^+^ cells identified in the mLNs and LPMC also displayed DC-SIGN, in agreement with a previous report that showed high levels of DC-SIGN expression by IHC in the mucosa of CD patients ([@bib54]). This phenotype is reminiscent of in vitro--generated Mo-DCs ([@bib3]) and the Mo-DCs detected in the lymphoid organs of infected mice([@bib13]), but contrasts with recently described CD14^+^DC-SIGN^−^CD1c^+^ inflammatory DCs detected in the synovial fluid of rheumatoid arthritis patients ([@bib47]). Definitive classification of HLA-DR^+^CD172a^+^ cells into MΦ versus inflammatory Mo-DCs awaits further morphological and molecular studies.

In contrast to murine CD103^−^CD11b^+^ MΦ, which all express CD172a and CX~3~CR1 in LP, whether they are inflammatory or not, CD172a^+^ cells comprised only ∼15% of the HLA-DR^+^ cells in inflamed gut mucosa, with about ∼40% displaying CX~3~CR1. In mice, CD172a marks all myeloid cells, including lung and intestinal MΦ, as well as granulocytes and mucosal CD103^−^CD11b^+^ DCs in the skin, airway, and gut ([@bib19]; [@bib21]; [@bib40]). Murine CD11b^+^CX~3~CR1^+^ cells are considered as resident mucosal tissue MΦ because these cells cannot be retraced as a homogenous population in the LNs ([@bib45]). The CD11c^high^CD11b^+^CX~3~CR1^low^ DCs (also called CD11c^+^ MΦ) mediate pro-Th17 cell function, as opposed to CD11c^−^CD11b^+^CX~3~CR1^high^ MΦ (bona fide MΦ; [@bib36]). Subdivisions according to the levels of CX~3~CR1 expression in CX~3~CR1-GFP mice provide further evidence for a functional dichotomy. The CX~3~CR1^high^ cells retain a noninflammatory profile during intestinal inflammation, whereas CX~3~CR1^low^ cells accumulate in the inflamed mucosa ([@bib61]). The latter may develop into the former at steady state ([@bib4]). However, the human CD172a^+^CX~3~CR1^+^ cells described in this study appear distinct from the resident CD11c^−^CD11b^−^CD14^−^HLA-DR^+^CD13^+^ MΦ that represent the largest population of mononuclear phagocytes in the human body ([@bib51]; [@bib50]). The killing and elimination of invading pathogens are the primary functions of human intestinal MΦ. As such, the intestinal MΦ are essentially protective ([@bib50]). Because the ubiquitously expressed CD47 Ag delivers a "do not eat me" signal to CD172a^+^ APC, the lack of CD172a expression on resident human intestinal MΦ may facilitate their phagocytic function ([@bib55]).

The challenge with human studies is to define which of the circulating monocyte or DC populations may represent the precursors of the HLA-DR^+^CD172a^+^ cells detected in the lymphoid and nonlymphoid tissues. The inflammatory CD14^bright^ monocytes, which are the human counterparts of murine Ly6C^high^ cells, may represent candidate precursors of the proinflammatory CD14^+^ cells in the gut or Mo-DCs in the mLNs ([@bib53]). Of interest, autologous CD14^+^ monocytes injected into CD patients are retraced as intestinal CD14^+^ cells, and the transfer of Ly6C^high^ cells into mice generates CD103^−^CX~3~CR1^+^ mononuclear phagocytes ([@bib23]; [@bib56]). Here, we showed that the proportion of circulating HLA-DR^+^CD172a^bright^CD14^bright^CD16^−^ monocytes is similar in PBL from control and CD donors. However, HLA-DR^+^CD172a^+^CD14^+^ cells accumulated in the inflamed colons, in agreement with the detection of CD14^bright^CD103^−^ cells in the ileum of CD donors ([@bib4]). We further postulate that intestinal HLA-DR^+^CD172a^+^ cells that may coexpress E-Cadherin and/or CX~3~CR1 have the capacity to migrate into mLNs because they were also found in increased proportions in the mLNs of CD patients. Recent studies indicate that CD103^−^CX~3~CR1^+^CD172a^+^ mononuclear phagocytes, previously considered as a nonmigratory intestinal cell population, traffic from gut to mLNs in mice ([@bib11]; [@bib18]). However, the HLA-DR^+^CD172a^+^CD1c^−^CX~3~CR1^+^cells, which coexpress CD14 and E-Cadherin, may originate from circulating CD14^+^ monocytes that are recruited directly to mLNs from the bloodstream ([@bib49]; [@bib53]).

Human CD14^+^ MΦ produce IL12p40, TNF, IL-6, and IL-1β in response to in vitro culture with commensal bacteria ([@bib26]). Our data demonstrated that, among the ex vivo--isolated HLA-DR^+^ cells, only those that coexpressed CD172a and were recognized by CD47-Var1 produced IL-1β in the absence of external stimuli in the gut mucosa and mLNs. The inflammasome is a crucial molecular platform that regulates the activation of caspase-1 and the processing of IL-1β. However, how the main effectors of the inflammasome, IL-1 and IL-18, contribute to the development and perpetuation of IBD is rather complex ([@bib34]; [@bib38]). In brief, the protective function of these mediators, which involves epithelial cell repair, contrasts with their pathogenic role in maintaining intestinal inflammation. The increased production of IL-1β by HLA-DR^+^CD172a^+^ cells at inflamed sites in CD patients reinforces the idea that the overproduction of IL-1β correlates with overt inflammation and enhanced disease susceptibility in CD patients with Nod2 mutations ([@bib59]). Here, we further demonstrated that CD47 fusion protein profoundly alters the in vitro proinflammatory cytokine profile released from inflamed mucosal explants, including those extracted from patients who were refractory to anti-TNF therapy. More specifically, exposure to CD47-Var1 disabled HLA-DR^+^CD172a^+^ cells by reducing IL-1β, IL-6, IL-8, TNF, and, to a lesser extent, IL-23 release. CD47-Var1 also reduced IL-10 production. Although intestinal epithelial cells represent a major source of IL-10 in noninflamed gut tissues, the release of IL-10 was augmented in inflamed colons, corroborating earlier studies ([@bib2]). These data suggest that local IL-10 is insufficient to control overt inflammation in CD colons. In that regard, treatment with IL-10 does not ameliorate human CD nor established murine experimental colitis ([@bib24]). Furthermore, TNF, IL-6, and IL-8 secretion was restricted to CD172a^+^ cells, that include HLA-DR^+^ (inflammatory DCs) and HLA-DR^−^ cells (neutrophils) in the LP of CD patients.

The frequency of IL-23^+^CD68^+^ MΦ is augmented in situ in inflamed tissues ([@bib43]). Together with IL-23, IL-1β can promote the generation of Th17 cells ([@bib1]). Recent studies have supported the concept that CD is a Th1/Th17-associated autoinflammatory disease ([@bib29]). Our data indicate that CD47-Var1 impaired the ability of HLA-DR^+^CD172a^+^ CX~3~CR1^−^ cells isolated from mLNs of CD donors, to stimulate in vitro memory Th17, Th17/Th1 but not Th1 responses. The CD47 fusion protein, when administered in vivo*,* could also reduce the recruitment of colitogenic CD172a^+^ cells to tissues and mLNs ([@bib19]). In that regard, our results indicate that CD47-Var1 decreased the production of MIP-1α, which is reported to attract inflammatory monocytes to inflamed gut ([@bib44]).

Collectively, we have identified functional HLA-DR^+^CD172a^+^ cells, which are increased in the mLNs and intestines of CD patients, and conclude that these cells represent the human counterparts of murine colitogenic DCs. Confusion still remains regarding the classification of these mononuclear phagocytes as Mo-DCs or MΦ in peripheral tissues. HLA-DR^+^CD172a^+^ cells are an important source of proinflammatory cytokines, and therefore, we propose to refer to these cells as monocyte-derived effector cells (MDECs) or inflammatory DCs, as they appear to be distinct from classical DCs, monocytes, and MΦ in LP. In addition, MDECs are distinct from the anergic resident intestinal MΦ because they represent an important source of TNF and IL-1β in the mucosal tissues and mLNs of CD patients. The binding of the CD47 fusion protein to MDECs reflects the expression of CD172a, which becomes a suitable target for CD. Indeed, the suppression of multiple cytokines through a rather selective target, i.e., the proinflammatory CD172a^+^ MDECs and perhaps CD172a^+^ neutrophils, while sparing the protective CD172a^−^ cells (tolerogenic CD103^+^ DCs, cCLE9A/CD141^+^ cells, and resident LP MΦ) might offer a therapeutic advantage over single-agent therapies. Indeed, only 50% of CD patients achieved remission under single anti-TNF or anti-IL12p40 treatments, the best currently available treatments for this debilitating chronic IBD. In conclusion, the administration of the CD47 fusion protein opens a novel therapeutic avenue for IBD patients.

MATERIALS AND METHODS
=====================

### Clinical tissue samples.

CD patients and non-IBD control donors (largely medical check-ups, colon cancer, or diverticulitis cases) were recruited from the gastroenterology and digestive tract surgery departments at Centre Hospitalier de L'Université de Montréal (CHUM) in compliance with the Institutional CHUM Ethic Research Committee, and written informed consent was obtained from all patients. Peripheral blood samples were collected from all donors (non-IBD, *n* = 30; IBD, *n* = 67). Intestinal tissue samples were obtained from endoscopic biopsies (colons) or surgically resected specimens (colon, *n* = 29; ileum, *n* = 7). Specimens were obtained from unaffected areas of control donors or noninflamed and inflamed regions of CD patients on the basis of clinical, endoscopic and histological findings according to established criteria. The mLNs were obtained from surgical specimens. Peripheral blood samples were also obtained from healthy volunteers in compliance with the Swiss Red Cross Center, Basel.

### Intestinal tissue explant cultures.

Dissected mucosal tissues (∼100 mg/piece) were cultured in RPMI 1640 medium (Wisent) supplemented with 10% FCS (Wisent) and an antibiotic cocktail (10 µg/ml of Vancomycin; Hospira), 50 µg/ml of Meropenem (AstraZeneca Canada), 50 µg/ml of Gentamicin (Invitrogen), 2.5 µg/ml of Fungizone (Invitrogen), and 12.5 µg/ml of polymyxin B (Invitrogen) in a 70% O~2~ and 5% CO~2~ saturated 37°C culture incubator for 24 h. In some experiments, CD47-Var1 fusion protein or IgG1 control fusion protein (Novartis Institute, Basel, Switzerland) was added at a concentration of 10 µg/ml. The culture supernatants were collected, and the proinflammatory cytokine profile was assessed using MAP technology (Inflammation MAP v1.0; Myriad RBM). The data were normalized by the weight of the tissue and culture volume. Data are presented as the absolute amount of cytokine released from 100 mg of tissue.

### Cellular suspension preparation.

PBMC were prepared by density gradient centrifugation of heparinized peripheral blood. In some experiments, WBCs were obtained by hemolyzing the whole blood with ACK lysing buffer (Lonza, Basel, Switzerland). LPMC were isolated from intestinal specimens using a modification of the protocol described by [@bib10]. In brief, the dissected mucosal tissue was cut into small pieces, incubated in HBSS (Sigma-Aldrich) containing 1 mM DTT and 1 mM EDTA (Sigma-Aldrich) for 45 min at 37°C and enzymatically digested with 0.25 mg/ml of collagenase D (Roche) and 0.01 mg/ml of DNase I (Roche) for 45--60 min at 37°C along with mechanical dissociation using a gentleMACS Dissociator (Miltenyi Biotec). Mesenteric LNs were harvested and passed through a 70-µm pore mesh to obtain the cellular suspension.

### Flow cytometry analysis.

Whole blood cells (hemolyzed), PBMCs, mLN cells, and LPMCs were stained for surface antigens and fixed and stained for intracellular cytokine expression using fluoresceinated monoclonal antibodies to CD1c, CD4, CD8, CD11c, CD14, CD16, CD62L, CD66b, CD123, CD172a (clone SE5A5), CD172b (clone B4B6), CD197 (CCR7), CX~3~CR1, HLA-DR, IL-1β, IL-6, IL-8, IL-10, and TNF (BioLegend), CD45, CD209 (DC-SIGN) and CD324 (E-Cadherin; BD), Slan (Miltenyi Biotec), MHC class II (ID Laboratories), Alexa Fluor 647--conjugated CD47-Var1, and IgG1 control fusion proteins (Novartis Institute). Data were acquired and analyzed using the BD FACS Aria II system. FACS analysis was performed on CD45^+^ gated hematopoietic cells in LPMCs. The mean fluorescent intensity (MFI) ratio of positive and negative populations was used to normalize the signals to the background.

### HLA-DR^+^CD172a^+^/memory CD4 T cell co-cultures.

Two subsets of effector memory CD45RA^−^CD25^−^CD62L^lo^CD4 T cells (CCR7^−^ and CCR7^+^; [@bib30]) were isolated from mLNs. T cells were either cultured with 100 U/ml of IL-2 (R&D Systems) for 24 h in 96-well round-bottom plates in RPMI 1640 medium supplemented with 10% FCS penicillin and streptomycin or co-cultures with autologous HLA-DR^+^CD172a^+^ cells (CD14^+^CX~3~CR1^+^, CD14^−^CX~3~CR1^+^, and CD14^−^CX~3~CR1^−^) at a 5:1 ratio for 5 d in the presence of *Staphylococcus aureus cowan 1* (at a dilution of 1/20,000) and CD47-Var1 or IgG1 control fusion proteins (10 µg/ml; [@bib63]). T cells were restimulated by PMA (Sigma-Aldrich) and ionomycin (EMD Millipore) for the last 6 h of culture. Brefeldin A (EMD Millipore) was further added in the last 3 h of restimulation culture. Cell surface CD2 (BioLegend) staining followed by intracytoplasmic staining for IL-17 (R&D Systems) and IFN-γ (BioLegend) was performed and then analyzed by flow cytometry.

### Statistical analysis.

The statistical analyses were performed on untransformed data unless otherwise indicated. Paired Student's *t* tests or Wilcoxon paired tests were performed where applicable. For nonpaired data, Mann-Whitney tests or unpaired Student's *t* tests with Welch correction were used. The Pearson test was used for correlation significance analysis.
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